Related Experiment Videos
Changing strategies in the management of chronic congestive heart failure
1Creighton University Cardiac Center, Omaha, NE 68131.
Insights
Current congestive heart failure (CHF) drug therapy guidelines recommend diuretics, digoxin, and ACE inhibitors for symptomatic patients. Avoid certain agents like beta-agonists due to high mortality risks.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Chronic congestive heart failure (CHF) management has evolved with recent drug therapy insights.
- Understanding treatment strategies for different stages of CHF, from asymptomatic to severe, is crucial.
Purpose of the Study:
- To outline current evidence-based drug therapy recommendations for patients with chronic congestive heart failure (CHF).
- To identify effective treatment combinations and agents to avoid in CHF management.
Main Methods:
- Review of recent studies defining the role of drug therapy in chronic congestive heart failure (CHF).
- Analysis of treatment guidelines for different New York Heart Association (NYHA) classes of CHF.
Main Results:
- For symptomatic CHF (NYHA class II-IV), initial treatment should combine diuretics, digoxin, and ACE inhibitors to reduce mortality.
- Adding hydralazine and nitrates may benefit persistent symptomatic patients, though not extensively studied with ACE inhibitors.
- Agents like beta-agonists and phosphodiesterase inhibitors are associated with high mortality and should be avoided.
Conclusions:
- Current drug therapy for symptomatic CHF focuses on a combination of diuretics, digoxin, and ACE inhibitors.
- Careful consideration of drug choices is essential to improve outcomes and avoid adverse effects in CHF patients.
- Early consideration of heart transplantation is advised for eligible patients to preserve organ function.
Abstract:
Recent studies have more clearly defined the role of drug therapy in patients with chronic congestive heart failure (CHF). Treatment of patients with asymptomatic left ventricular dysfunction (New York Heart Association [NYHA] class I) cannot be recommended at this time. The benefit of prophylactic treatment with angiotensin-converting enzyme inhibitors (ACEIs) or vasodilators in patients at high risk for developing symptomatic CHF is currently being evaluated. Treatment of patients with symptomatic CHF (NYHA class II-IV) should be initiated with a combination of a diuretic, digoxin, and an ACEI. This combination has been shown to reduce the mortality rate in patients with NYHA class II-IV CHF. Patients who remain symptomatic despite treatment with this combination may benefit from the addition of the direct-acting, nonspecific vasodilators--hydralazine and a nitrate. The addition of the nonspecific vasodilators to an ACEI has not been tested in controlled trials. In patients who remain symptomatic despite treatment with diuretics, digoxin, ACEIs, and nonspecific vasodilators, treatment options are not clear. The use of beta-agonists, phosphodiesterase inhibitors, and intermittent fixed-dose, fixed-interval dobutamine should be avoided as these agents are associated with a high mortality rate. Heart transplantation should be considered early in the course of CHF to allow for preservation of other vital organ systems. Unfortunately, heart transplantation is available to only a very small minority of potential transplant candidates.